Anika Therapeutics (ANIK) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.81 -1.05%
Revenue Growth %: +7.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +7.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.54, $0.01 better than the analyst estimate of $0.53. Revenue for the quarter came in at $28.7 million versus the consensus estimate of $27.84 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
